220 related articles for article (PubMed ID: 29302046)
1. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
Maughan BL; Guedes LB; Boucher K; Rajoria G; Liu Z; Klimek S; Zoino R; Antonarakis ES; Lotan TL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):260-268. PubMed ID: 29302046
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
[TBL] [Abstract][Full Text] [Related]
3. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
4. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
[TBL] [Abstract][Full Text] [Related]
5. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
7. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
[TBL] [Abstract][Full Text] [Related]
8. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
9.
De Laere B; Oeyen S; Mayrhofer M; Whitington T; van Dam PJ; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert EG; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff IE; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden GG; Rutten A; Del Favero J; Rantalainen M; Rajan P; Sleijfer S; Ullén A; Yachnin J; Grönberg H; Van Laere SJ; Lindberg J; Dirix LY
Clin Cancer Res; 2019 Mar; 25(6):1766-1773. PubMed ID: 30209161
[TBL] [Abstract][Full Text] [Related]
10. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489
[TBL] [Abstract][Full Text] [Related]
11. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
12. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Hashimoto K; Tabata H; Shindo T; Tanaka T; Hashimoto J; Inoue R; Muranaka T; Hotta H; Yanase M; Kunishima Y; Takahashi A; Masumori N;
Urol Oncol; 2019 Jul; 37(7):485-491. PubMed ID: 31103335
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
De Laere B; Rajan P; Grönberg H; Dirix L; Lindberg J;
JAMA Oncol; 2019 Jul; 5(7):1060-1062. PubMed ID: 31046065
[TBL] [Abstract][Full Text] [Related]
14. [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Richter I; Dvořák J; Hejzlarová V; Chalupa J; Sochor M; Stankuš I; Barsová L; Holikova M; Forster J; Bartoš J
Klin Onkol; 2016; 29(2):127-32. PubMed ID: 27081803
[TBL] [Abstract][Full Text] [Related]
15. Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.
Maughan BL; Luber B; Nadal R; Antonarakis ES
Prostate; 2017 Jan; 77(1):33-40. PubMed ID: 27527643
[TBL] [Abstract][Full Text] [Related]
16. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
18. Association among metabolic syndrome, inflammation, and survival in prostate cancer.
Conteduca V; Caffo O; Galli L; Maugeri A; Scarpi E; Maines F; Chiuri VE; Lolli C; Kinspergher S; Schepisi G; Santoni M; Santini D; Fratino L; Burgio SL; Salvi S; Menna C; De Giorgi U
Urol Oncol; 2018 May; 36(5):240.e1-240.e11. PubMed ID: 29402534
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
